Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 12, 2017DiabetologiaOpen Access

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

View Full Paper
Ask AI
Bookmark
Share

Authors

GFGian Paolo FadiniCross-Cutting CardiologyBBBenedetta Maria BonoraUniversity of PaduaAAAngelo AvogaroUniversity of Pisa

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fadini et al. (2017) studied this question.

synapsesocial.com/papers/69fc2dfd30300db352fa3cc7https://doi.org/10.1007/s00125-017-4301-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,293 citations
  2. 2Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)2014 · 109 citations
  3. 3Novel Statistical Tools for Monitoring the Safety of Marketed Drugs2007 · 265 citations
  4. 4Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes2016 · 727 citations